Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic
Lewis Buss, Carlos A. Prete, Claudia M. M. Abrahim, et al.
Science (2021) Vol. 371, Iss. 6526, pp. 288-292
Open Access | Times Cited: 518

Showing 1-25 of 518 citing articles:

Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil
Nuno R. Faria, Thomas A. Mellan, Charles Whittaker, et al.
Science (2021) Vol. 372, Iss. 6544, pp. 815-821
Open Access | Times Cited: 1435
The biological and clinical significance of emerging SARS-CoV-2 variants
Kaiming Tao, Philip L. Tzou, Janin Nouhin, et al.
Nature Reviews Genetics (2021) Vol. 22, Iss. 12, pp. 757-773
Open Access | Times Cited: 977
Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence
Éster Cerdeira Sabino, Lewis Buss, Maria P. S. S. Carvalho, et al.
The Lancet (2021) Vol. 397, Iss. 10273, pp. 452-455
Open Access | Times Cited: 856
Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies
Delphine Planas, Timothée Bruel, Ludivine Grzelak, et al.
Nature Medicine (2021) Vol. 27, Iss. 5, pp. 917-924
Closed Access | Times Cited: 732
Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant
Xianding Deng, Miguel Garcia-Knight, Mir M. Khalid, et al.
Cell (2021) Vol. 184, Iss. 13, pp. 3426-3437.e8
Open Access | Times Cited: 514
COVID-19 in Amazonas, Brazil, was driven by the persistence of endemic lineages and P.1 emergence
Felipe Gomes Naveca, Valdinete Alves do Nascimento, Victor Costa de Souza, et al.
Nature Medicine (2021) Vol. 27, Iss. 7, pp. 1230-1238
Open Access | Times Cited: 431
Genomic Characterization of a Novel SARS-CoV-2 Lineage from Rio de Janeiro, Brazil
Carolina Moreira Voloch, Ronaldo da Silva Francisco, Luiz Gonzaga Paula de Almeida, et al.
Journal of Virology (2021) Vol. 95, Iss. 10
Open Access | Times Cited: 374
Tackling COVID-19 with neutralizing monoclonal antibodies
Davide Corti, Lisa A. Purcell, Gyorgy Snell, et al.
Cell (2021) Vol. 184, Iss. 12, pp. 3086-3108
Open Access | Times Cited: 370
Novel SARS-CoV-2 variants: the pandemics within the pandemic
Erik Boehm, Ilona Kronig, Richard A. Neher, et al.
Clinical Microbiology and Infection (2021) Vol. 27, Iss. 8, pp. 1109-1117
Open Access | Times Cited: 358
The variant gambit: COVID-19’s next move
Jessica A. Plante, Brooke Mitchell, Kenneth S. Plante, et al.
Cell Host & Microbe (2021) Vol. 29, Iss. 4, pp. 508-515
Open Access | Times Cited: 343
Spatiotemporal pattern of COVID-19 spread in Brazil
Márcia C. Castro, Sun Kim, Lorena Barberia, et al.
Science (2021) Vol. 372, Iss. 6544, pp. 821-826
Open Access | Times Cited: 315
Reduced sensitivity of infectious SARS-CoV-2 variant B.1.617.2 to monoclonal antibodies and sera from convalescent and vaccinated individuals
Delphine Planas, David Veyer, Artem Baidaliuk, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Closed Access | Times Cited: 278
Outbreak.info genomic reports: scalable and dynamic surveillance of SARS-CoV-2 variants and mutations
Karthik Gangavarapu, Alaa Abdel Latif, Julia L. Mullen, et al.
Nature Methods (2023) Vol. 20, Iss. 4, pp. 512-522
Open Access | Times Cited: 273
Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19
Carmen Gómez, Beatriz Perdiguero, Mariano Estéban
Vaccines (2021) Vol. 9, Iss. 3, pp. 243-243
Open Access | Times Cited: 267
Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection
Deborah Cromer, Jennifer A. Juno, David S. Khoury, et al.
Nature reviews. Immunology (2021) Vol. 21, Iss. 6, pp. 395-404
Open Access | Times Cited: 258
Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis
Ryan M Barber, Reed J D Sorensen, David M. Pigott, et al.
The Lancet (2022) Vol. 399, Iss. 10344, pp. 2351-2380
Open Access | Times Cited: 254
Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation
Xianding Deng, Miguel Garcia-Knight, Mir M. Khalid, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 238
Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes
Chadi M. Saad-Roy, Sinead E. Morris, C. Jessica E. Metcalf, et al.
Science (2021) Vol. 372, Iss. 6540, pp. 363-370
Open Access | Times Cited: 233
Genomics and epidemiology of a novel SARS-CoV-2 lineage in Manaus, Brazil
Nuno R. Faria, Thomas A. Mellan, Charles Whittaker, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 190
Pandemic Prevention: Lessons from COVID-19
Mario Coccia
Encyclopedia (2021) Vol. 1, Iss. 2, pp. 433-444
Open Access | Times Cited: 181
Burden and characteristics of COVID-19 in the United States during 2020
Sen Pei, Teresa K. Yamana, Sasikiran Kandula, et al.
Nature (2021) Vol. 598, Iss. 7880, pp. 338-341
Open Access | Times Cited: 180
Optimal levels of vaccination to reduce COVID-19 infected individuals and deaths: A global analysis
Mario Coccia
Environmental Research (2021) Vol. 204, pp. 112314-112314
Open Access | Times Cited: 179
Anti-Spike Protein Assays to Determine SARS-CoV-2 Antibody Levels: a Head-to-Head Comparison of Five Quantitative Assays
Thomas Perkmann, Nicole Perkmann‐Nagele, Thomas Köller, et al.
Microbiology Spectrum (2021) Vol. 9, Iss. 1
Open Access | Times Cited: 177
Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial
Ana Cristina de Medeiros Ribeiro, Nádia Emi Aikawa, Carla Gonçalves Schahin Saad, et al.
Nature Medicine (2021) Vol. 27, Iss. 10, pp. 1744-1751
Open Access | Times Cited: 175
Page 1 - Next Page

Scroll to top